Tiny silica nanoparticles spark tumor death and boost immunotherapy in mouse prostate cancer

Researchers engineered ultrasmall silica nanoparticles (Cornell Prime dots) that target prostate tumors, trigger ferroptosis (iron-driven cell death), and remodel the tumor immune environment to a more active state. In mouse models of aggressive prostate cancer, these particles alone modestly improved survival, but when combined with immune checkpoint therapy they produced complete or near-complete remissions and indefinite survival in 4 of 10 mice, rising to 5 of 10 with an added CSF-1R blockade. The treatment localized to tumors with no observed toxicity in healthy tissues. If safety and efficacy translate to humans, this approach could move toward clinical trials as a multi-pronged cancer therapy that enhances immunotherapy effectiveness.